However , b- and y-type ions of the CID-MS2 spectra (supplemental Fig. one GalNAc unit to either Thr-99 or Thr-101, forming a core glycopeptide intended for subsequent additions of in all 11 GalNAc residues to selected Ser and Thr residues from the Thr-76Lys-107 stretch of the mucin domain. The expression patterns of GalNAc transferases in the infected cells suggested that initial additions of GalNAc were carried out by initiating GalNAc transferases, in particular GalNAc-T2, whereas subsequent GalNAc additions were carried out by followup transferases, in particular GalNAc-T10. Essentially all of the susceptible Ser or Thr residues had to acquire their GalNAc models before any elongation to longerO-linked glycans of the gC-1-associated GalNAc models was permitted. Because the GalNAc occupancy pattern is of relevance for receptor binding of gC-1, the data provide a model to delineate biosynthetic actions ofO-linked glycosylation of the gC-1 mucin domain name in HSV-1-infected target cells. == Intro == Herpes simplex virus type 1 (HSV-1) encodes 12 diverse glycoprotein species that are exposed on the viral envelope and during the late phases from the infectious cycle also in the membranes from the infected cells (1, 2). Five of those glycoproteins, designated gB-1, gC-1, gD-1, gH-1, and gL-1, are implicated in viral attachment and subsequent uptake of computer virus particles into the infected cell (13). One of the first steps in this process is binding of virus-associated gC-1 to specific glycosaminoglycan species at the surface from the target cell (4, 5). In addition to its functions in viral attachment, gC-1 also contributes to immune evasion by functioning as a decoy receptor intended for factor C3b of the enhance system (6), and recent data suggest that gC-1 may also express selectin ligands, e. g. sialyl Lewis X (sLex), with the capacity to participate in viral pathogenesis (7, 8). The peptide sequence of gC-1 comprises 511 amino acid residues, and the protein is heavily glycosylated, that contains 9 consensus sites forN-linked glycosylation scattered along the peptide sequence and a major mucin-like domain that contains numerous clusteredO-linked glycans in a peptide stretch delimited by amino acids 30 and 124 (9). The molecular size of theO-linked glycans of the gC-1 mucin domain name may vary from monosaccharides to Manidipine (Manyper) sialylated tetrasaccharides (7, 10, 11) but possibly also larger structures (8, 12). In vitrostudies using HSV-1 mutants expressing gC-1 that lack its mucin domain name indicated that this domain is involved not only in viral binding to its target cell but also in cell-to-cell spread of virus, which is affected by the number ofO-linked glycans in this domain name (13, 14). Moreover, the mucin domain name of gC-1 appears to be involved in expression of virus-induced selectin ligands, a phenomenon of possible relevance for viraemic spread of HSV-1 (8, 12, 15, 16). Despite the significance from the gC-1 mucin domain it remains unclear how this region acquires its content ofO-linked glycans. Initiation ofO-linked glycosylation of viral glycoproteins and thus the addition of a GalNAc residue to a serine (Ser) or threonine (Thr) residue of the mucin domain is carried out in the Golgi network by one or more of 20 host cell-encoded polypeptide GalNAc transferases, designated GalNAc-Ts (encoded by the human being genesGALNT1throughT20) (17, 18). The 20 diverse GalNAc-Ts add GalNAc to Ser/Thr Manidipine (Manyper) residues in mucin domains rich in Ser, Thr, and Pro, with different but partly overlapping specificities regarding the amino acid sequence in the peptide acceptors. Based on similarities in these peptide acceptor specificities, the GalNAc-Ts may be divided in several subgroups (17, 1921). There are examples of Ser/Thr-containing proteins taking GalNAc addition by only 1 of the 20 different GalNAc-Ts (2023), demonstrating the existence of unique peptide specificities among the GalNAc-Ts. All TNFRSF9 but one of the GalNAc-Ts (GalNAc-T20) also include a lectin domain name that can hole to GalNAc residues of an acceptor mucin domain, thereby affecting the specificity from the enzyme (2426). According to the current notion, the addition of the innermost GalNAc models to their respective Ser and Thr sites in the mucin domains is carried out in two actions (26, 27). First, specific GalNAc-Ts (e. g. Manidipine (Manyper) the ubiquitously expressed isoforms GalNAc-T1 and -T2 referred to as the initiating GalNAc-Ts) add GalNAc units to the naked polypeptide. This initial glycosylation paves the way intended for the subsequent action of followup GalNAc-Ts (e. g. GalNAc-T4, -T7, and -T10 (28, 29)), which depends on the presence of preexisting GalNAc models on the peptide backbone enabling the addition of GalNAc to neighboring free Ser or Thr amino acid.